Keros Therapeutics (KROS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Keros Therapeutics

NasdaqGM•Healthcare•Biotechnology

$11.19-0.17(-0.01%)After hours

Market Cap

$224.93M

P/S

15.0x

P/B

0.9x

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

How this company scores

WeakMetricSide Score: 36/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (5/25).

Profitability8/25

Growth5/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Long cash runwayInterest easily coveredNet cash positionNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 8.7x5y range 8.7x – 98.1x

Currently below its 4-quarter median.

P/S · 15.0x5y range 1.9x – 118228.0x

Currently below its 17-quarter median.

P/B · 0.9x5y range 0.6x – 5.8x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Cash Burn

Watch

6 of the last 8 quarters had negative FCF — inconsistent cash generation raises sustainability concerns.

Price & Volume

Market Cap $224.93M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $15.01M
Q. Revenue: $0
TTM EBITDA: $-99.10M
TTM Op. Income: $-101.47M
Q. Op. Income: $-30.94M
TTM Net Income: $-83.16M
Q. Net Income: $-28.71M
EPS: $-1.45
Shares Out.: $19.80M

$15.01M in TTM revenue declined 93.6% YoY, reaching $0 last quarter. TTM EBITDA of $-99.10M and TTM operating income of $-101.47M show growth is flowing through to the bottom line. However, net income is negative at $83.16M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -3093700000.0%
Net Margin: -2871000000.0%

Op. margin of -3093700000.0% is down 3093699780.8% YoY — costs are rising relative to revenue. Net margin at -2871000000.0% Over the past year, operating margin is down 1411616586% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 15.0x
P/B Ratio: 0.9x

P/S of 15.0x and P/B of 0.9x. P/S is high, meaning growth expectations are priced in. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $287.60M
Cash: $257.61M
Long-Term Debt: N/A
Book Value: $262.32M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-20.42M
TTM Free Cash Flow: $-48.49M
FCF Margin: -322.9%
FCF / Net Income: 0.6

TTM FCF of $-48.49M on $-20.42M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 191% — an improving trend.